AMENDMENTS TO THE SPECIFICATION

Please amend the specification as follows:

Please replace the third full paragraph on page 3 with the following amended paragraph:

--FIG. 1 is a graph which illustrates the pharmacodynamic effect (testosterone suppression) obtained by subcutaneous injection in rats of a suspension of ~~Teverelix®~~ Teverelix trifluoroacetate according to the invention; and--

Please replace the fourth full paragraph on page 3 with the following amended paragraph:

--FIG. 2 is a graph which illustrates the sustained release of the peptide ~~Teverelix®~~ Teverelix. for several weeks in rats injected with the suspension of ~~Teverelix®~~ Teverelix trifluoroacetate according to the invention.--

Please replace the first full paragraph on page 6 with the following amended paragraph:

-- A specific discovery was that a highly concentrated aqueous suspension of the peptide of the formula Ac--D--Nal--D--pClPhe--D--Pal--S- er--Tyr--D--Hci--LeuLys(iPr)--Pro--D--Ala--NH_2 (~~Teverelix®~~ Teverelix, a GnRH antagonist) as a trifluoroacetate (TFA) or sulfate salt does not, as might be expected by its hydrophobic character, form a gel but instead forms a microcrystalline milky suspension which is easy to inject parenterally in animals or humans, and which releases the active principle over several weeks (see FIGS. 1 and 2). Such behavior is not elicited by other salts such as the acetate, which result in the expected, but unwanted, formation of gels with poor bioavailability in vivo.--

Please replace the third full paragraph on page 6 with the following amended paragraph:

--200 μL of 5% mannitol were added to approximately 15 mg of the LHRH antagonist ~~Teverelix®~~ Teverelix trifluoroacetate. The mixture was stirred using vortex during one minute and a flowing milky pearly suspension was obtained. The suspension is made of microcrystals of about 10 μm length. Microcrystals may clump together to form urchin like structures. The suspension was injected in rats (1 mg) sub-cutaneously and provided the pharmacodynamic effect of testosterone suppression for more than 45 days (FIG. 1). The pharmacokinetic analysis showed a sustained release of the peptide for several weeks (FIG. 2).--

Please replace the fourth full paragraph on page 6 with the following amended paragraph:

-- 200 μL of water were added to approximately 15 mg of the LHRH antagonist ~~Teverelix®~~ Teverelix trifluoroacetate. The mixture was stirred using vortex during one minute and a flowing milky pearly suspension was obtained.--

Please replace the first full paragraph on page 7 with the following amended paragraph:

--200 μL of water were added to approximately 15 mg of the LHRH antagonist ~~Teverelix®~~ Teverelix acetate. The mixture was stirred using vortex during one minute and a transparent gel was obtained. The addition of 20 μL of TFA (3 mols/mol) to the gel resulted in the formation of a fluid, flowing milky pearly suspension.--

Please replace the second full paragraph on page 7 with the following amended paragraph:

-- 200 μL of 100 mM TFA were added to approximately 15 mg of the LHRH antagonist ~~Teverelix®~~ Teverelix acetate (2 mols/mol) to obtain a flowing milky suspension. In addition, mixing 200 μL of 75 mM TFA with approximately 15 mg of the LHRH antagonist ~~teverelix®~~ Teverelix acetate (1.5 mol/mol) resulted in a transparent gel being

obtained after mixing. In another study, 100 µL of TFA of various concentrations were added to 7.5 mg of the LHRH antagonist ~~teverelix®~~ Teverelix acetate, with the TFA/Teverelix molar ratio ranging from 1 to 3. A flowing milky suspension was obtained with molar ratios of 1.6, whereas gels were obtained at other molar ratios.--

Please replace the third full paragraph on page 7 with the following amended paragraph:

--200 µL of 150 mM TFA were added to amounts of the LHRH antagonist ~~Teverelix®~~ Teverelix acetate ranging from 5 to 30 mg (concentration ranging from 25 to 150 mg/ml). A flowing milky suspension was obtained with concentrations up to 100 mg/ml.--

Please replace the fourth full paragraph on page 7 with the following amended paragraph:

--200 µL of 150 mM TFA were added to approximately 15 mg of the LHRH antagonist ~~Teverelix®~~ Teverelix acetate (3 mols/mol) and a flowing milky suspension was obtained after mixing. The suspension was freeze-dried over-night. 200 µL of water or 5% mannitol were added to the lyophilisate and a flowing milky suspension was obtained after mixing and reconstitution.--

Please replace the first full paragraph on page 8 with the following amended paragraph:

--1 mL of 150 mM TFA were added to approximately 75 mg of the LHRH antagonist ~~Teverelix®~~ Teverelix acetate (3 mols/mol) and a flowing milky suspension was obtained after mixing. The suspension was freeze-dried over-night. 1 mL of water and 0.2M acetate buffer pH 4.0 were added to the lyophilisate and a flowing milky suspension was obtained after mixing and reconstitution. These suspensions were stable for at least 3 days at room temperature.--

Please replace the second full paragraph on page 8 with the following amended paragraph:

-- 100 μL of a 250 mM H_2SO_4 were added to 7.5 mg of the LHRH antagonist ~~Teverelix®~~ Teverelix acetate (5 mols/mol) and a flowing milky suspension was obtained after several hours. The suspension is made of microcrystals of about 100 μm length. Microcrystals may assemble together to form urchin like structures. The suspension was freeze-dried over-night. 100 μL of water or 5% mannitol were added to the lyophilisate and a flowing milky suspension was obtained after mixing and reconstitution.--

Please replace the third full paragraph on page 8 with the following amended paragraph:

-- 100 μL of a 150 mM trifluoromethane sulfonic acid solution were added to 7.5 mg of ~~Teverelix®~~ Teverelix acetate to obtain a free flowing milky suspension after mixing.--

Please replace the fourth full paragraph on page 8 with the following amended paragraph:

-- 100 μL of a 150 mM solution of benzenesulfonic acid were added to 7.5 mg ~~Teverelix®~~ Teverelix hydrochloride to give after a mixing a free flowing suspension.--

Please replace the first full paragraph on page 9 with the following amended paragraph:

-- 100 μL of a 200 mM solution of trifluoroacetic acid solution were added to 2.5 mg of ~~Cetrorelix ®~~ Cetrorelix acetate to obtain a milky free flowing suspension.--